Payment overview · 2025
General Payments
$758.37
21 reported records · 7 companies
Healthcare provider profile · identity verified
Maria E Romero, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANNAPOLIS, MD · NPI 1336328079
Verified facts
What the public records show
CMS Open Payments records show Maria E Romero, MD received $758.37 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $297.46 | 39.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $167.00 | 22.0% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $114.36 | 15.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.71 | 11.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.92 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.60 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.32 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.37 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $251.82 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.74 | 5 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $86.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $53.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.92 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.44 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| PatientCare Link Normalized: patientcare link |
Device | Boston Scientific Corporation | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 330 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 89 |
| Losartan Potassium | Losartan Potassium | 302 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 227 | 60 |
| Metformin Hcl | Metformin Hcl | 140 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 39 |
| Lisinopril | Lisinopril | 127 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 32 |
| Gabapentin | Gabapentin | 96 | 32 |
| Furosemide | Furosemide | 95 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 94 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 27 |
| Sertraline Hcl | Sertraline Hcl | 88 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 27 |
| Alendronate Sodium | Alendronate Sodium | 75 | 21 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Simvastatin | Simvastatin | 69 | 24 |
| Trazodone Hcl | Trazodone Hcl | 66 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 19 |
| Omeprazole | Omeprazole | 61 | 17 |
| Synthroid | Levothyroxine Sodium | 58 | 17 |
| Lorazepam | Lorazepam | 54 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 28 |
| Meloxicam | Meloxicam | 53 | 17 |
| Ezetimibe | Ezetimibe | 52 | 18 |
| Famotidine | Famotidine | 52 | 20 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Metformin Hcl Er | Metformin Hcl | 49 | 15 |
| Carvedilol | Carvedilol | 48 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 36 |
| Eliquis | Apixaban | 45 | 15 |
| Tramadol Hcl | Tramadol Hcl | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Ozempic | Semaglutide | 43 | 12 |
| Desloratadine | Desloratadine | 42 | 15 |
| Allopurinol | Allopurinol | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 14 |
| Potassium Chloride | Potassium Chloride | 39 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Febuxostat | Febuxostat | 36 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 13 |
| Atenolol | Atenolol | 35 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Prednisone | Prednisone | 35 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 28 |
| Azithromycin | Azithromycin | 33 | 27 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 22 |
| Glimepiride | Glimepiride | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 17 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Colchicine | Colchicine | 19 | 11 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.37 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, BodyGuardian, MOUNJARO, Ozempic, PatientCare Link, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error